SGTI Receives U.S. Patent for Injuv®

SGTI Receives U.S. Patent for Injuv®

LOS ANGELESSoft GelTechnologies Inc. (SGTI) was awarded U.S. Patent No. 6,806,259, Hyaluronicacid in soft gel form, covering its Injuv® soft gelatin capsule formulation.Injuv is a low molecular weight hyaluronic acid (HA) ingredient derived fromrooster combs; HA works to retain fluids in body tissues, including the synovialfluid, cartilage and vitreous humor of the eye. The patent covers the Injuv softgel formulation to provide the primary benefit of internally causing thesoftening of the human skin.

The patent is the latest for SGTI, which also holds patentsfor GlucoTrim®, CoQsol® and Isomer E. This additional patent strengthensSGTIs position as a leading source for unique, clinically proven, effectivenutraceuticals, said Ron Udell, president of SGTI (www.soft-gel.com).Wehave just completed a clinical trial with an Injuv formulation and the resultson improving skin appearance and texture were considered significant by theresearchers.